COVID-19 vaccination rates vary by community vulnerability: A county-level analysis

•County vulnerability scores were associated with reduced COVID-19 vaccination.•Vaccination was most negatively related to housing type/composition vulnerability.•Efforts should focus on increasing access among marginalized populations. We used the COVID-19 Community Vulnerability Index and 7 theme...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Vaccine 2021-07, Vol.39 (31), p.4245-4249
Hauptverfasser: Brown, Clare C., Young, Sean G., Pro, George C.
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:•County vulnerability scores were associated with reduced COVID-19 vaccination.•Vaccination was most negatively related to housing type/composition vulnerability.•Efforts should focus on increasing access among marginalized populations. We used the COVID-19 Community Vulnerability Index and 7 theme scores to assess associations between vulnerability and county-level COVID-19 vaccination (n = 2415 counties) through May 25th, 2021. When comparing vaccination rates among quintiles of CCVI scores, Theme 3 (housing type, transportation, household composition, and disability) was associated with the largest disparity, with the least vulnerable counties (Q1) having 33% higher rates of vaccination among individuals aged 18+ (53.5% vs 40.2%) compared to counties with the highest vulnerability (Q5). Using generalized linear models with binomial distributions and log links, we found that a 10-point increase in the CCVI index, socioeconomic vulnerability, housing type and composition, and epidemiological factors were associated with at least a 1.0 percentage point decline in county-level vaccination. The association between community vulnerability and lower vaccination rates suggests the need for continued efforts for equitable COVID-19 vaccination across marginalized communities.
ISSN:0264-410X
1873-2518
DOI:10.1016/j.vaccine.2021.06.038